Comparative Pharmacology
Head-to-head clinical analysis: FERNISONE versus FLUDROCORTISONE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERNISONE versus FLUDROCORTISONE ACETATE.
FERNISONE vs FLUDROCORTISONE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FERNISONE is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased prostaglandin and leukotriene synthesis, and suppression of inflammatory mediators.
Mineralocorticoid receptor agonist; promotes sodium reabsorption and potassium excretion in renal distal tubules, increasing extracellular fluid volume. Also has glucocorticoid activity.
40 mg orally once daily
0.1 mg orally once daily, range 0.05-0.2 mg/day
None Documented
None Documented
Terminal elimination half-life: 18-24 hours in healthy adults. In elderly (age >65), half-life increases to 30-36 hours due to reduced renal function. In moderate renal impairment (CrCl 30-60 mL/min), half-life extends to 40-48 hours. Clinical context: requires dose adjustment in renal impairment; steady-state reached in 3-5 days.
Terminal elimination half-life is 3.5 hours (range 2–5 h); clinical effect duration exceeds half-life due to mineralocorticoid receptor binding.
Renal excretion of unchanged drug and metabolites: ~60% (30% unchanged, 30% metabolites). Biliary/fecal elimination: ~35% (primarily as metabolites). Minor metabolic clearance via CYP3A4. About 5% eliminated in sweat and saliva.
Renal (80%) as inactive metabolites; less than 5% unchanged; minor biliary/fecal elimination.
Category C
Category D/X
Corticosteroid
Corticosteroid